| 1 |
34428285 | Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. | 2022 Feb 24 |
1 |
| 2 |
34638128 | A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. | 2022 Apr 12 |
1 |
| 3 |
34668817 | Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. | 2022 Feb |
1 |
| 4 |
34764434 | BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis. | 2022 Apr |
1 |
| 5 |
34843406 | Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). | 2022 Jan 20 |
1 |
| 6 |
34851173 | The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review. | 2022 Feb |
1 |
| 7 |
34904799 | Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. | 2022 Jan 27 |
1 |
| 8 |
35089671 | Current Frontline Treatment of Diffuse Large B-Cell Lymphoma. | 2022 Jan 20 |
1 |
| 9 |
35096395 | Diffuse large B-cell lymphoma with uncommon cardiac invasion. | 2022 |
1 |
| 10 |
35158997 | Primary Effusion Lymphoma: A Clinicopathologic Perspective. | 2022 Jan 30 |
1 |
| 11 |
35317846 | RNA-Seq analysis of gene expression in 25 cases of canine lymphoma undergoing CHOP chemotherapy. | 2022 Mar 22 |
1 |
| 12 |
35392483 | Prognostic Stratification of Diffuse Large B-cell Lymphoma Using Clinico-genomic Models: Validation and Improvement of the LymForest-25 Model. | 2022 Apr |
1 |
| 13 |
35451406 | Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma. | 2022 Mar 11 |
1 |
| 14 |
35468783 | Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis. | 2022 Apr 25 |
1 |
| 15 |
35486884 | Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. | 2022 Mar |
1 |
| 16 |
35573753 | COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma. | 2022 Apr |
1 |
| 17 |
33592897 | Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report. | 2021 Feb 5 |
1 |
| 18 |
33625586 | Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. | 2021 Sep |
1 |
| 19 |
33688781 | Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. | 2021 Aug |
1 |
| 20 |
33728177 | Sarcoidosis-Lymphoma Syndrome Presenting As Bony Vertebral Metastasis: A Case Report and Literature Review. | 2021 Feb 8 |
1 |
| 21 |
33734921 | R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma: a systematic review and meta-analysis. | 2021 Jun |
1 |
| 22 |
33796235 | Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. | 2021 |
1 |
| 23 |
33944646 | Burden of illness and treatment patterns among patients with peripheral T-cell lymphoma in the US healthcare setting. | 2021 Jul |
1 |
| 24 |
33989279 | Lenalidomide in DLBCL: are we past the cell of origin? | 2021 May |
1 |
| 25 |
34007370 | MYC-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge. | 2021 Apr |
1 |
| 26 |
34022150 | Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial. | 2021 Jul |
1 |
| 27 |
34075009 | Baseline 18F-FDG PET textural features as predictors of response to chemotherapy in diffuse large B-cell lymphoma. | 2021 Nov 1 |
1 |
| 28 |
34124276 | Suppression of DLBCL Progression by the E3 Ligase Trim35 Is Mediated by CLOCK Degradation and NK Cell Infiltration. | 2021 |
1 |
| 29 |
34265889 | Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis. | 2021 Sep |
1 |
| 30 |
34327076 | CD5+ Diffuse Large B-Cell Lymphoma With Leukemic Transformation: A Rare Case With Central Nervous System Involvement, Treated With R-CHOP and Intrathecal Methotrexate/Cytarabine. | 2021 Jun |
1 |
| 31 |
34565287 | Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. | 2021 Dec |
2 |
| 32 |
34586105 | Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma. | 2021 Sep |
1 |
| 33 |
34668281 | Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance. | 2021 Oct 20 |
1 |
| 34 |
34676685 | Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphoma. | 2021 Dec |
1 |
| 35 |
34732441 | Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma. | 2021 Nov |
2 |
| 36 |
34815635 | Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. | 2021 Oct 31 |
1 |
| 37 |
34872317 | Incidence and risk factors of pneumonia in diffuse large B-cell lymphoma patients receiving first line R-CHOP/R-CHOP-like immunochemotherapy: a retrospective study of 287 patients in single center. | 2021 Nov |
1 |
| 38 |
34990523 | Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia During R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma. | 2021 Dec 31 |
1 |
| 39 |
31902733 | Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. | 2020 Feb |
1 |
| 40 |
31940809 | Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? | 2020 Jan 11 |
1 |
| 41 |
32042095 | Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. | 2020 Oct |
1 |
| 42 |
32112707 | Double-Hit and Triple-Hit Follicular Lymphoma. | 2020 Apr 15 |
1 |
| 43 |
32187361 | Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. | 2020 May 14 |
1 |
| 44 |
32250167 | ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. | 2020 May |
1 |
| 45 |
32417940 | Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. | 2020 Jul |
1 |
| 46 |
32505213 | A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. | 2020 Jun 6 |
1 |
| 47 |
32648457 | Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center. | 2020 Jul |
1 |
| 48 |
32651429 | Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. | 2020 Jul 10 |
1 |
| 49 |
32658627 | Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. | 2020 Sep 10 |
1 |
| 50 |
32722779 | Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. | 2020 Jul 28 |
1 |